Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Takeshi Arashiro; Yuzo Arima; Jin Kuramochi; Hirokazu Muraoka; Akihiro Sato; Kumi Chubachi; Atsushi Yanai; Hiroko Arioka; Yuki Uehara; Genei Ihara; Yasuyuki Kato; Naoki Yanagisawa; Akihiro Ueda; Hideaki Kato; Hideaki Oka; Yusuke Nishida; Yuki Nidaira; Takahiro Asami; Torahiko Jinta; Akira Nakamura; Kunihiro Oba; Daisuke Taniyama; Kei Yamamoto; Katsushi Tanaka; Kankuro Ueshima; Tetsuji Fuwa; Ashley Stucky; Tadaki Suzuki; Chris Smith; Martin Hibberd; Koya Ariyoshi; Motoi Suzuki

doi:10.1093/ofid/ofad240

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Takeshi Arashiro, Yuzo Arima, Jin Kuramochi, Hirokazu Muraoka, Akihiro Sato, Kumi Chubachi, Atsushi Yanai, Hiroko Arioka, Yuki Uehara, Genei Ihara, Yasuyuki Kato, Naoki Yanagisawa, Akihiro Ueda, Hideaki Kato, Hideaki Oka, Yusuke Nishida, Yuki Nidaira, Takahiro Asami, Torahiko Jinta, Akira NakamuraKunihiro Oba, Daisuke Taniyama, Kei Yamamoto, Katsushi Tanaka, Kankuro Ueshima, Tetsuji Fuwa, Ashley Stucky, Tadaki Suzuki, Chris Smith, Martin Hibberd, Koya Ariyoshi, Motoi Suzuki

Research output: Contribution to journal › Article › peer-review

11 Citations (Scopus)

Abstract

In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

Original language	English
Article number	ofad240
Journal	Open Forum Infectious Diseases
Volume	10
Issue number	6
DOIs	https://doi.org/10.1093/ofid/ofad240
Publication status	Published - 01-06-2023
Externally published	Yes

All Science Journal Classification (ASJC) codes

Oncology
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ofid/ofad240

Cite this

Arashiro, T., Arima, Y., Kuramochi, J., Muraoka, H., Sato, A., Chubachi, K., Yanai, A., Arioka, H., Uehara, Y., Ihara, G., Kato, Y., Yanagisawa, N., Ueda, A., Kato, H., Oka, H., Nishida, Y., Nidaira, Y., Asami, T., Jinta, T., ... Suzuki, M. (2023). Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan. Open Forum Infectious Diseases, 10(6), Article ofad240. https://doi.org/10.1093/ofid/ofad240

@article{1dec6b9081794441bf218ac5583079cf,

title = "Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan",

abstract = "In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).",

keywords = "COVID-19, SARS-CoV-2, SARS-CoV-2 variants, test-negative design, vaccine effectiveness",

author = "Takeshi Arashiro and Yuzo Arima and Jin Kuramochi and Hirokazu Muraoka and Akihiro Sato and Kumi Chubachi and Atsushi Yanai and Hiroko Arioka and Yuki Uehara and Genei Ihara and Yasuyuki Kato and Naoki Yanagisawa and Akihiro Ueda and Hideaki Kato and Hideaki Oka and Yusuke Nishida and Yuki Nidaira and Takahiro Asami and Torahiko Jinta and Akira Nakamura and Kunihiro Oba and Daisuke Taniyama and Kei Yamamoto and Katsushi Tanaka and Kankuro Ueshima and Tetsuji Fuwa and Ashley Stucky and Tadaki Suzuki and Chris Smith and Martin Hibberd and Koya Ariyoshi and Motoi Suzuki",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America.",

year = "2023",

month = jun,

day = "1",

doi = "10.1093/ofid/ofad240",

language = "English",

volume = "10",

journal = "Open Forum Infectious Diseases",

issn = "2328-8957",

publisher = "Oxford University Press",

number = "6",

}

Arashiro, T, Arima, Y, Kuramochi, J, Muraoka, H, Sato, A, Chubachi, K, Yanai, A, Arioka, H, Uehara, Y, Ihara, G, Kato, Y, Yanagisawa, N, Ueda, A, Kato, H, Oka, H, Nishida, Y, Nidaira, Y, Asami, T, Jinta, T, Nakamura, A, Oba, K, Taniyama, D, Yamamoto, K, Tanaka, K, Ueshima, K, Fuwa, T, Stucky, A, Suzuki, T, Smith, C, Hibberd, M, Ariyoshi, K & Suzuki, M 2023, 'Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan', Open Forum Infectious Diseases, vol. 10, no. 6, ofad240. https://doi.org/10.1093/ofid/ofad240

TY - JOUR

T1 - Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

AU - Arashiro, Takeshi

AU - Arima, Yuzo

AU - Kuramochi, Jin

AU - Muraoka, Hirokazu

AU - Sato, Akihiro

AU - Chubachi, Kumi

AU - Yanai, Atsushi

AU - Arioka, Hiroko

AU - Uehara, Yuki

AU - Ihara, Genei

AU - Kato, Yasuyuki

AU - Yanagisawa, Naoki

AU - Ueda, Akihiro

AU - Kato, Hideaki

AU - Oka, Hideaki

AU - Nishida, Yusuke

AU - Nidaira, Yuki

AU - Asami, Takahiro

AU - Jinta, Torahiko

AU - Nakamura, Akira

AU - Oba, Kunihiro

AU - Taniyama, Daisuke

AU - Yamamoto, Kei

AU - Tanaka, Katsushi

AU - Ueshima, Kankuro

AU - Fuwa, Tetsuji

AU - Stucky, Ashley

AU - Suzuki, Tadaki

AU - Smith, Chris

AU - Hibberd, Martin

AU - Ariyoshi, Koya

AU - Suzuki, Motoi

PY - 2023/6/1

Y1 - 2023/6/1

N2 - In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

AB - In this multicenter, prospective, test-negative, case-control study in Japan, the effectiveness of both BA.1-containing and BA.4/BA.5-containing bivalent coronavirus disease 2019 mRNA vaccines against symptomatic infection during the BA.5-dominant period was high compared with no vaccination (65% and 76%) and moderate compared with monovalent vaccines administered over half a year earlier (46% combined).

KW - COVID-19

KW - SARS-CoV-2

KW - SARS-CoV-2 variants

KW - test-negative design

KW - vaccine effectiveness

UR - http://www.scopus.com/inward/record.url?scp=85164238334&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85164238334&partnerID=8YFLogxK

U2 - 10.1093/ofid/ofad240

DO - 10.1093/ofid/ofad240

M3 - Article

AN - SCOPUS:85164238334

SN - 2328-8957

VL - 10

JO - Open Forum Infectious Diseases

JF - Open Forum Infectious Diseases

IS - 6

M1 - ofad240

ER -

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this